Damora Therapeutics (DMRA) Research & Development (2019 - 2026)
Damora Therapeutics posted quarterly Research & Development of $23.8 million for Q1 2026, up 3406.93% year-on-year from $678000.0 in Q1 2025, and up 1.97% on a QoQ basis from $23.3 million in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Research & Development data on file, last reported at $23.8 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 3406.93% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $50.0 million (up 983.37% YoY), and the FY2025 full-year result was $26.9 million, up 320.08% from the prior year.
- Research & Development for Q1 2026 stood at $23.8 million, up from $23.3 million in the prior quarter.
- Across five years, Research & Development topped out at $23.8 million in Q1 2026 and bottomed at $678000.0 in Q1 2025.
- The 5-year median for Research & Development is $2.8 million (2023), against an average of $7.6 million.
- The widest annual swing landed in 2024, when Research & Development sank 77.33%; it then surged 3406.93% in 2026.
- A 5-year view of Research & Development shows it stood at $10.8 million in 2022, then sank by 74.3% to $2.8 million in 2023, then sank by 63.58% to $1.0 million in 2024, then soared by 2213.29% to $23.3 million in 2025, then climbed by 1.97% to $23.8 million in 2026.
- The last three Research & Development figures came in at $23.8 million (Q1 2026), $23.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 23.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.78 Mn |
| Dec 31, 2025 | 23.32 Mn |
| Sep 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 2.55 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | 10.36 Mn |
| Dec 31, 2022 | 10.77 Mn |
| Sep 30, 2022 | 10.49 Mn |
| Jun 30, 2022 | 13.71 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 10.12 Mn |
| Sep 30, 2021 | 9.75 Mn |
| Jun 30, 2021 | 8.64 Mn |
| Mar 31, 2021 | 9.99 Mn |
| Dec 31, 2020 | 7.75 Mn |
| Sep 30, 2020 | 7.65 Mn |
| Jun 30, 2020 | 4.52 Mn |
| Mar 31, 2020 | 4.71 Mn |
| Dec 31, 2019 | 7.85 Mn |
| Sep 30, 2019 | 3.67 Mn |